Tech rules Monday's stock market — plus, Eli Lilly's big comeback and new vote of confidence

The market saw modest gains, primarily driven by AI-related technology stocks and the "Magnificent Seven," with Amazon notably rising on a $38 billion OpenAI deal. Eli Lilly extended its post-earnings rally, recovering significantly and announcing a $3 billion manufacturing investment in the Netherlands to expand GLP-1 production, signaling strong confidence in its portfolio despite prior competitive concerns. Meanwhile, recent spin-offs are being re-evaluated, with Qnity Electronics receiving multiple "buy" ratings from analysts, while Solstice is expected to experience near-term volatility as its shareholder base shifts. Several companies are also slated to report earnings in the coming days.

Analysis

The market experienced modest upward movement, primarily propelled by AI-related technology stocks and the "Magnificent Seven," with the S&P 500 and Nasdaq showing slight gains. Amazon notably contributed to this rally following its significant $38 billion multiyear compute capacity deal with OpenAI, alongside positive developments for Nvidia. This concentration of gains underscores the continued investor focus on high-growth tech narratives.

Eli Lilly demonstrated robust performance, extending its post-earnings rally for a third consecutive session, achieving approximately a 9% gain since its beat-and-raise Q3 report and returning to the upper $800s. This recovery indicates that the competitive impact from Novo Nordisk's Wegovy deal was less severe than initially feared. The company's plan to invest $3 billion in a new Netherlands manufacturing facility, specifically for oral GLP-1s like orforglipron, signals strong confidence in its future portfolio and global supply chain expansion.

Following the completion of the Honeywell and DuPont spin-offs, attention is shifting to the new entities. Qnity Electronics has garnered significant analyst interest, with five major firms initiating coverage with "buy" or equivalent ratings and an average price target of $113, positioning it as a favored semiconductor materials play. Solstice is anticipated to experience near-term trading volatility as its shareholder base transitions, yet it presents interesting secular growth opportunities, particularly in nuclear energy, as evidenced by UBS's $62 price target.

Key Decisions for Investors

• Investors should maintain exposure to high-growth AI and Magnificent Seven stocks, particularly those with specific catalysts like Amazon's $38 billion OpenAI deal.
• Evaluate Eli Lilly for continued strength, given its strategic $3 billion manufacturing investment in GLP-1s and demonstrated resilience against competitive pressures.
• Consider Qnity Electronics as a potential long opportunity, supported by strong initial analyst coverage and an average price target of $113, while approaching Solstice with caution due to anticipated near-term volatility.
• Adjust price targets for Honeywell and DuPont to reflect the value loss from recent spin-offs and monitor the remaining Honeywell entity for its planned future split.